Graphite Bio, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. -0.32%332.560.0%$4439.04m
BNTXBioNTech SE 2.10%268.380.0%$738.42m
NVAXNovavax, Inc. -15.50%135.6679.4%$600.84m
AMGNAmgen, Inc. 1.58%210.061.4%$554.98m
SNSSSunesis Pharmaceuticals, Inc. 4.89%6.440.7%$450.18m
REGNRegeneron Pharmaceuticals, Inc. 1.66%561.282.7%$438.75m
GILDGilead Sciences, Inc. 0.37%67.151.0%$414.60m
CCXIChemoCentryx, Inc. 2.96%34.652.9%$396.80m
ILMNIllumina, Inc. -0.18%413.333.3%$373.95m
XLRNAcceleron Pharma, Inc. -0.47%172.925.3%$348.67m
VRTXVertex Pharmaceuticals, Inc. 0.33%186.021.9%$270.65m
BIIBBiogen, Inc. -0.51%266.771.7%$242.30m
OCGNOcugen, Inc. 4.08%8.670.0%$183.61m
XENEXenon Pharmaceuticals, Inc. 1.88%30.370.4%$163.39m
CRSPCRISPR Therapeutics AG -1.63%98.630.6%$159.49m

Company Profile

Graphite Bio, Inc. operates as a clinical-stage gene editing company. It focuses on therapies that harness targeted gene integration to treat or cure serious diseases. The company was founded by Matthew Porteus and Maria Grazia Roncarolo in June 2017 and is headquartered in South San Francisco, CA.